Table 3 Subgroup analyses of paricalcitol compared with other VDRAs for target reduction of iPTH from baseline
Subgroup | No.patients | No.trials | Relative Risk(95% CI) | P Value | I2(%) | Test of Interaction, P |
|---|---|---|---|---|---|---|
Total | 696 | 5 | 1.01 (0.87,1.18) | 0.85 | 31 | Not applicable |
Baseline iPTH level | ||||||
  < 68.4 pmol/L | 407 | 3 | 0.97 (0.78,1.20) | 0.77 | 51 | 0.49 |
  > 68.4 pmol/L | 289 | 2 | 1.09 (0.84,1.42) | 0.51 | 13 |  |
Types of dialysis | ||||||
 Hemodialysis | 670 | 4 | 1.03 (0.87,1.20) | 0.76 | 41 | 0.44 |
 Peritoneal dialysis | 26 | 1 | 0.78 (0.39,1.55) | 0.47 | 31 |  |
Routine of administration | ||||||
 Oral | 92 | 2 | 0.82 (0.61,1.11) | 0.21 | 0 | 0.14 |
 Intravenous | 604 | 3 | 1.07 (0.91,1.26) | 0.42 | 38 |  |
Sample size | ||||||
 Small, n < 100 | 178 | 3 | 0.98 (0.75,1.28) | 0.87 | 42 | 0.82 |
 Large, n > 100 | 518 | 2 | 1.02 (0.79,1.32) | 0.88 | 60 |  |
Risk of bias | ||||||
 Low quality | 92 | 2 | 0.82 (0.61,1.11) | 0.21 | 0 | 0.14 |
 High quality | 604 | 3 | 1.07 (0.91,1.26) | 0.42 | 38 |  |